

COVID-19: A model correlating BCG vaccination to protection from mortality implicates trained immunity - SUPPLEMENTAL DATA, TABLES & NOTES

SUPPLEMENTAL DATA & SUPPLEMENTAL NOTES

Supplemental Tables

1. **Table 1** of 100 countries ranked by mortality data and BCG vaccination status
2. **Table 2** of Multiple time snapshots (Ranked) of COVID19 deaths in each country vs BCG history

Supplemental note accompanying Supplemental Tables

1. For this analysis, we addressed the temporal dimension of the COVID19 pandemic. This is challenging as there are so few time series data available (e.g. there is only three weeks' of mortality data available). For example, only 3 and a half weeks ago (March 14) there were only 2 deaths in Germany and 5 in the UK. Three days prior, the 4th highest mortality "country" was a cruise ship (population 2600) the Diamond Princess with 6 deaths. China, Italy and Iran had the top 3 highest mortality rankings.
2. Ordinarily it would have been preferred to have more data, to enable (for example) the calculation of the decline in the daily rate of deaths or relative second derivative of total deaths per country. This would more accurately model the severity of the pandemic from a mathematical point of view. However, due to the lack of data volume, this was not possible at present. In short we aim to "find the asymptote" for each country on our analysis of mortality vs time. This involves two steps, firstly more temporal data must be gathered in order to plot an approximate function with higher confidence (currently we have not achieved this point in terms of data). And secondly using a suitable regression technique, discern the actual function from which we can easily calculate the asymptote using the standard equations. The choice of regression and tools remains open but in general the data should follow a function of the type $f(x) = a / (1 + b c^{-x})$, which is the well known Logistic Function. The key variable we would solve for being "a", the horizontal asymptote or limiting value as it is known in models of resource limited growth. Of course there are many assumptions around this, to be validated further.
3. Based on the above, we employed a simplified approach that used 'snapshot' dates to take into account the start time of the pandemic per country. We analysed data from countries with the most data points available (although some had limited trustworthy data) and the smallest intervals that smoothed out the inconsistent daily reporting from each country's health authority (many countries with significant death numbers were taking 3 days to correct figures due to stretched health workers, death certification processes and government departments).
4. Since there was a time cost for data collection of higher quality BCG usage history (obtained and cross referenced from multiple sources Supplemental Figure 1), we focussed on the top 100 countries with available mortality data. Outliers, both positive and negative were assessed separately. By the end of March only 100 countries (Supplemental Table 1) had reported fatality data. Further analyses at later stages should re-evaluate this assumption as more nations report.
5. We selected our common starting point once total confirmed deaths of COVID-19 for each country reached 0.1 deaths per million inhabitants. This seemingly arbitrary starting point afforded a good balance between; a start time late enough per country to be aware of the pandemic enough; to track deaths (e.g. 5 confirmed deaths for a 50 million population), and also early enough to include as many countries as possible. This also provided a 3 to 4 week period of data up to the present for enough countries for dynamic temporal patterns to emerge. As mentioned

above, any further analysis at a later stage should re-evaluate this assumption as more nations report data.

Supplemental Note 1

Confounding Factors

1. Multiple efforts are underway, in several countries, that can effectively suppress the spread of the pandemic and act to ultimately lower death rates. Some of these such as testing, tracking and tracing of COVID19 infected individuals are well reported and have been used with remarkable effectiveness resulting in a strong reduction in deaths per million. Apart from South Korea, Singapore and Taiwan, the extent of this practice is hard to quantify. At this stage in the pandemic no good tools exist to correct for their suppression of fatalities, though backward looking epidemiological models may be able to approximate their effectiveness.
2. Some of the published prior art has used World Bank Income data to remove and “clean” some of the data. In theory this may remove some noise due to undersampling in poorer countries. However, in the case of BCG vaccination, this has the actual effect of removing signal due to a far greater number of “poorer” countries engaged in BCG vaccination. As mentioned earlier we correct for this by removing populations below 1 million inhabitants, and more significantly focus only on fatalities per million inhabitants (and explain the few outliers separately). Importantly, there are high income countries engaged in BCG vaccination with high quality data that are well along their pandemic paths to enable for good data to be obtained (Japan, South Korea and Taiwan). In addition there are several BCG vaccinating nations where mortality is so low they have not pierced the 0.1 per million threshold and for this reason their influence on the mortality per capita analysis dilutes the weight of BCG as a factor.
3. [BCG vaccine compliance](#), (Supplemental Figure 1) and the dates on which it was either initiated or stopped are also very important as pitfalls in analysis. Indeed some highly authoritative sources of data such as the [BCG atlas](#) are unable to provide comprehensive data for all countries. To correct for this variable we closely cross-examined the atlas against [WHO](#), World Bank and even local data. For example, we scrutinized well [curated datasets](#) (for example recorded deaths, age and prefecture of origin of every Japanese national deceased from COVID-19) and checked this against the date when BCG vaccination first occurred in that prefecture 70 years ago. The data are highly revealing indicating a sharp delineation at the time vaccination begins. Japan began countrywide BCG vaccination in 1951 with BCG vaccination occurring beginning in 1947 in Tokyo and Osaka. Strikingly, of the 99 deaths from COVID19 to date in Japan only two are below the age of 70.
4. BCG Vaccine quality and by inference vaccine type (Supplemental Figure 1 & 2) could also be a confounding factor. In terms of BCG vaccine quality Japan is recognized to possess the best strain of the vaccine. We carefully traced vaccine quality and origin around the world relating it to protection from mortality especially in countries such as Iran which uses a locally produced strain for nearly 40yrs. In the case of Iran individuals above that age are unvaccinated. Published data

from the Chinese CDC has indicated that mortality was greatest in China in populations above the age of 60. This suggests that Iranians over the age of 40yrs old do not benefit directly from having been vaccinated by BCG. Data on the age structure of all COVID19 victims per country is difficult to obtain. The “flattening of the curve” of the Iran data (see Figure 1) beyond 14 days post 0.1 million fatalities suggests a more rapid attenuation of deaths distinct from other non-BCG vaccinating countries.

5. Human mobility as a confounder - Several countries have implemented social distancing and quarantines as the number of detected cases and fatalities have increased during the COVID19 pandemic. Some countries benefit from extreme geographic isolation and this attenuates deaths independently (New Zealand). These countries have variable success in suppressing the increase in fatalities. Historical epidemiological studies, especially those dating to the Spanish Flu pandemic of 1918 have shown the levels of efficacy social distancing and quarantines have shown in reducing fatalities. These measures coupled to hand washing, mask wearing and general hygiene all attenuate the spread of the epidemic and thus suppress fatalities. Though not directly linked to mobility, the presence of physical infrastructure from prior pandemics weighs in the favor of specific nations in the speed and efficacy of their responses, for example those of S. Korea (MERS) and Hong Kong (SARS). Epidemiological models are effective in weighting the impact of these measures. We are unable to do so in relationship to BCG vaccination at this time. Notably this variable should be independent enough of BCG status however in our data sample (there are suppression behaviors on either side of the high and low fatalities and on either side of the BCG status).
6. Other vaccines have been shown to elicit nonspecific protective effects highly similar to trained immunity. These include the oral polio vaccine (Aaby et al., 2005), measles vaccine administered as MMR (Aaby et al., 2010; Mina et al. 2015) and vaccinia vaccine (Blok et al., 2019). The preponderance of the administration of these vaccines concurrently with BCG make their influence difficult to deconvolve at this time. However, we aim to address the trained immunity components in COVID-19 protection for these three important vaccines in forthcoming studies and publications.
7. Age as a confounder. A leitmotif of COVID19 is the much higher risk of fatality that occurs in older aged individuals. A study from Japan controlling for life expectancy finds that “this BCG effect remained significant after controlling for the country’s life expectancy” (Sala & Miyakawa, 2020). Conversely, fatalities around the world are rare in children below the age of 10yrs old. Children have been identified as major spreaders of influenza (Heikkinen 2006). In the current COVID19 pandemic our analysis of BCG versus nonBCG vaccinating countries cannot reveal the role of children since there is insufficient data to examine fatalities in the age group. However, there are hints in the data that populations where young people are routinely vaccinated whilst older populations have been unvaccinated have a slower growth in fatalities. With more data over time these effects will be more easily quantified.
8. Comorbidities of certain chronic diseases act as strong confounders and the contribution of BCG in neutralizing these is unclear. The CDC China identified cardiovascular disease, hypertension, diabetes and obesity as the four key major comorbidities associated with COVID19. Quantifying this alongside vaccination contribution should be part of ongoing research but many countries in

our study also have low death per capita from COVID-19 and high rates of Diabetes, Heart Disease, Obesity. As we point out in this study, sufficient data to quantify *how much* protection is afforded by BCG vaccination will emerge in the coming months as more data points accrete in our model. This becomes very important when large populations which are HIV positive (which is immunosuppressive) are exposed to COVID19. An important situation is that of South Africa with nearly 8 million HIV positive individuals but a mandatory BCG vaccination program that vaccinates within days after birth.


Supplemental note 2

Outliers


1. The case of Lebanon as an outlier, based on the graph in Figure 1, bears further investigation into the possible reasons for its strong proximity in its “slope” to BCG vaccinated countries. Lebanon has a population of approximately 6.1 million. This population was 4 million just a decade ago. This dramatic growth in just a decade is due to immigration from fleeing refugees from neighboring countries, in particular Syria. All neighboring countries have mandatory BCG programs and the policies of Lebanon coordinated with the WHO, UNICEF and NGOs was to vaccinate all refugees especially children prioritizing polio vaccination (UNICEF EPI Report in Lebanon (2013-2017). The Lebanese government emphasized the preservation of Lebanon as a polio free area, aggressively making sure that all refugees received oral polio vaccination (OPV) as well as MMR vaccination. BCG vaccination while conducted was not as heavily enforced. The most significant insight from the Lebanese COVID19 fatality data is its relationship to OPV and MMR. As mentioned in [Supplemental Note 1 point \(6\)](#), both OPV (Aaby et al., 2005), and MMR (Aaby et al., 2010; Mina et al. 2015) are able to elicit nonspecific protective effects akin to trained immunity. Since BCG has been demonstrated to elicit its nonspecific protection by a similar mechanism we cannot exclude that Lebanon benefits from its mandatory coverage of OPV and MMR though we have insufficient data at this time to make this assertion confidently. Australia also has experienced a large relatively recent change in demographics which we found interesting (covered below).
2. The case of Portugal as an outlier is based on its high ranking in Table 1 in the low and medium confidence table, yet nominally being a BCG vaccinating country. A strong geographic proximity to Spain suggests the nonBCG vaccinated population would be larger. This is augmented by a large percentage of its population returned from former African colonies (Angola and Mozambique) in the mid-1970s (15% nearly 1 million individuals over two years) from countries with no BCG vaccination policy at that time. Therefore quantifying the long term compliance of BCG vaccination is difficult to assess. We do note that WHO records show 40 yrs ago there were no reported BCG vaccination numbers from Portugal and the earliest records from 1985 report 82% coverage.
3. The case of Ireland as an outlier is based on the graph in Figure 1 and bears further investigation into the possible reasons for its strong proximity in its “slope” to nonBCG vaccinated countries. While WHO records of BCG vaccination do not extend further than 1980, some important events in the Irish record emerge including (reported in The Irish Times) a stockout beginning in 2015 of extended duration over multiple years. However, compliance in Ireland (Supplemental Figure 3) even prior to the stockout was dramatically low with reported levels as low as 34% 2004. Importantly as far back as 1980 Ireland did not report any active BCG vaccination until 1985 meaning it is possible that individuals over 40 yrs old in Ireland did not systematically receive

BCG vaccinations and thereafter implementation of the policy was sporadic. See Supplemental Figure 3. How far back in time this lapse in compliance extends is data currently unavailable.


4. The case of Australia as an outlier is based on the graph in Figure 1 and bears further investigation into the possible reasons for its strong proximity in its “slope” to BCG vaccinated countries, though it is nominally a nonBCG vaccinating country. It also appears in Table 1, and in Supplemental Table 1 as a significant outlier. It is an outlier because it has no universal BCG vaccination policy except for immigrants to Australia, children who have at least one parent who is an immigrant and Aboriginal peoples. Australia has one of the highest immigrant populations in the world, 29% of the population are immigrants. This creates a significant part of the population with BCG coverage in the population. Its geographic location, similar to New Zealand, may also work to attenuate spread of infection and indirectly reduce mortality rates.



Supplemental Figure 1: Current BCG Vaccination programs worldwide as of April 2020,



Supplemental Figure 2: Current BCG strains used in vaccination programs worldwide. Data obtained from Ritz and Curtis, 2009.



Supplemental Figure 3: Large disparities between Official (Irish government) reported BCG vaccination compliance and estimated compliance reported from the WHO using actual vaccine batches.

References:

Aaby P, Hedegaard K, Sodemann M, Nhante E, Veirum JE, Jakobsen M, Lisse I, Jensen H, Sandström A. Childhood mortality after oral polio immunisation campaign in Guinea-Bissau. *Vaccine*. 2005 Feb 25;23(14):1746-51.

Aaby P, Martins CL, Garly ML, Balé C, Andersen A, Rodrigues A, Ravn H, Lisse IM, Benn CS, Whittle HC. Non-specific effects of standard measles vaccine at 4.5 and 9 months of age on childhood mortality: randomised controlled trial. *BMJ*. 2010 Nov 30;341:c6495.

Blok BA, Jensen KJ, Aaby P, Fomsgaard A, van Crevel R, Benn CS, Netea MG. Opposite effects of Vaccinia and modified Vaccinia Ankara on trained immunity. *Eur J Clin Microbiol Infect Dis*. 2019 Mar;38(3):449-456.

Irish Times

<https://www.independent.ie/irish-news/news/bcg-may-no-longer-be-a-routine-vaccine-for-children-hse-36594331.html>

Sala G, Miyakawa T. Association of BCG vaccination policy with prevalence and mortality of COVID-19. doi: <https://doi.org/10.1101/2020.03.30.20048165>

Mina MJ, Metcalf CJE, De Swart RL, Osterhaus A, Grenfell BT. Long-term measles-induced immunomodulation increases overall childhood infectious disease mortality. *Science* (2015) 348:694–9.

Heikkinen T. Influenza in children. *Acta Paediatr*. 2006 Jul;95(7):778-84. Review.

Ritz N, Curtis N. Mapping the global use of different BCG vaccine strains. *Tuberculosis (Edinb)*. 2009 Jul;89(4):248-51.

UNICEF evaluation report: https://www.unicef.org/evaldatabase/index_103529.html